Skip to content

Digital Lab Solutions AI Product Menu

PathAI is a leading IMS provider with deep expertise in algorithm development and with real-world experience from implementing AI in its own routine pathology laboratory. Thus, we offer a curated, multi-partner digital pathology ecosystem that gives labs seamless access to world-class algorithms that are fully integrated into AISight’s single viewer and workflow functionalities.

Workflow Optimization

ArtifactDetect

Automated detection of artifacts using action-oriented classes to support quality monitoring.

Learn More
ArtifactDetect-1

TumorDetect

Automated detection of tumor across all common carcinomas for case prioritization and case triaging.

Learn More
TumorDetect

AIM-TumorCellularity

Automate tumor-cellularity assessment for molecular testing workflows.

Learn More
AIM-TumorCellularity

Biomarker Quantification

AIM-PD-L1

Detect and quantify PD-L1+ tumor and immune cells. Available for biopharma and lab research use.

 

Learn More
hex-aiproduct-aimpdl1-400

AIM-IHC Breast Panel

AI-Based Measurement Panel of Key Breast Cancer Biomarkers — HER2, ER, PR, and Ki-67.

 

Learn More
aim-ihc-400w

AIM-MASH+

Automated and reproducible, AI-powered ordinal and continuous MASH CRN score component grades and fibrosis stage.

Learn More
hex-aiproduct-aimnash-400

PathAssist

PathAssist Derm

AI-assisted histopathology tool for specimen orientation, prioritization, and measurement.

Learn More
PathAssist Derm hexagon image

PathAI AI Partners

Deep Bio

DeepDx Prostate, is a CE-IVD-marked  diagnostic aid designed to enhance the precision of prostate cancer assessment in digital pathology.

Learn More

DoMore Diagnostics

Histotype Px® Colorectal is an outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection. It is CE-IVD-marked in EU.

Learn More

MindPeak

Mindpeak delivers CE-IVD-marked AI solutions for breast cancer biomarker analysis (HER2, ER/PR, Ki-67) and lung PD-L1, complemented by RUO assays for prostate, gastric, esophageal, urothelial
cancers, and onychomycosis in dermatopathology.

Learn More

Paige

Paige’s AI applications alleviate time and resource  pressures for pathologists. Paige’s AI suite includes solutions for Prostate, Breast, Colon, and Pan-Cancer.

Learn More

Primaa

Primaa offers AI-powered diagnostic tools such as Cleo Breast (CE-IVDR) and Cleo Skin (RUO) designed to detect and accurately quantify cancer biomarkers, lesion types, dimensions, margins, mitoses, and perineural invasion.

Learn More

Stratipath

Stratipath provides the first CE-IVD marked AI-based solution for prognostic risk profiling of breast cancer using routine histopathology slides.

Learn More

Visiopharm

Visiopharm offers a full breast panel of APPs (ER, PR, Ki-67, Metastasis Detection, and HER2) as well as an APP for non-small cell lung cancer (PD-L1). These APPs are cleared under IVDR in EU and UK and are RUO in the rest of world.

Learn More
guys-office-screen

Get in touch with our team

Learn more about our digital lab solutions.

Contact Us

ArtifactDetect is a workflow tool available on AISight® and AISight® Dx. AISight is for Research Use Only. Not for use in diagnostic procedures. AISight Dx is FDA-cleared for primary diagnosis in the US and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland.

TumorDetect, AIM-TumorCellularity, AIM-PD-L1, AIM-IHC Breast Panel, AIM-MASH and PathAssist Derm are for Research Use Only. Not for use in diagnostic procedures.